Ashley Lin

Ashley Lin is currently an MBA intern at ARCH Venture Partners since 2025, having previously served as an Investment Fellow at Necessary Ventures from August 2021 to January 2025, where responsibilities included due diligence and thesis building in TechBio, SynBio, platform therapeutics, and MedTech. Prior experience encompasses roles at Vir Biotechnology, Inc. as a Research Associate in Protein Chemistry, at Esper Biosciences as an intern developing diagnostic assays, and at Moderna as a Protein Sciences Co-Op involved in mRNA research. Additional research internships at Academia Sinica focused on protein interactions with SARS-CoV2, and at the Meinig School of Biomedical Engineering explored mechanisms related to congenital heart defects. Ashley Lin holds an MBA from the University of Chicago Booth School of Business and a BA in Biological Sciences and Chemistry from Cornell University.